Clinical Outcomes in Patients With Refractory Anemia With Excess Blasts (RAEB) Who Receive Hypomethylating Agents (HMAs)

We sought to understand the clinical effectiveness associated with use of hypomethylating agents (HMAs) azacitidine (AZA) and decitabine (DEC) for patients with refractory anemia with excess blasts (RAEB; an established proxy for higher-risk myelodysplastic syndromes/neoplasms) in contemporary and representative real-world settings.

Source: Clinical Lymphoma, Myeloma and Leukemia - October 28, 2023 Category: Hematology Authors: Amer M. Zeidan, Elizabeth S. Mearns, Carmen D. Ng, Anuj Shah, Neil Lamarre, Archibong Yellow-Duke, Neda Alrawashdh, Baiyu Yang, Wei-Han Cheng, Cat N. Bui, Anders Svensson Tags: Original Study Source Type: research